Zydus Lifesciences Limited has received final approval from the USFDA for Indocyanine Green for Injection USP, 25 mg/vial, along with 180 days of Competitive Generic Therapy (CGT) exclusivity. The approval allows Zydus to market the critical diagnostic imaging agent across U.S. hospital networks, strengthening its complex injectables portfolio.
AHMEDABAD, India — Indian pharmaceutical major Zydus Lifesciences Limited has secured final approval from the U.S. Food and Drug Administration (USFDA) to market Indocyanine Green for Injection USP, 25 mg/vial single-dose vials. Announced in a regulatory filing submitted to Indian stock exchanges, the approval grants Zydus 180 days of Competitive Generic Therapy (CGT) exclusivity. The development marks a key commercial milestone for the Ahmedabad-headquartered healthcare group, establishing it as a primary generic supplier for a critical diagnostic imaging agent across health systems in the United States.
Technical Scope and Manufacturing Specifications
According to regulatory documentation submitted by the pharmaceutical manufacturer, Zydus received Final Approval for its Abbreviated New Drug Application (ANDA) referencing the reference listed drug (RLD) IC-GREEN (Indocyanine Green for Injection, USP). The drug product is formulated as a sterile, lyophilized green powder supplied in 25 mg single-dose vials intended for intravenous administration.
| Product Parameter | Regulatory and Commercial Specification |
| Active Pharmaceutical Ingredient | Indocyanine Green USP |
| Dosage Form & Strength | Sterile Lyophilized Powder for Injection, 25 mg/vial |
| Reference Listed Drug (RLD) | IC-GREEN (Renew Pharmaceuticals Ltd.) |
| Exclusivity Designation | 180-Day Competitive Generic Therapy (CGT) Exclusivity |
| Primary Indication | Optical imaging for vascular, hepatic, and diagnostic mapping |
| Manufacturing Location | Injectable Manufacturing Facility, Jarod (Gujarat, India) |
The final approval allows Zydus Lifesciences to initiate commercial shipping directly to its U.S. subsidiary distribution channels, utilizing its automated injectables facility in Jarod, near Vadodara, Gujarat.
Clinical Indications and Market Demand
Indocyanine Green for Injection is a specialized diagnostic dye widely utilized across hospital surgical suites and clinical diagnostic departments. The agent binds rapidly to plasma proteins upon intravenous administration and is cleared almost exclusively by the liver into the bile, making it an essential diagnostic indicator.
Clinical applications for Indocyanine Green include:
Micro- and Macro-Vascular Perfusion: Real-time fluorescence visualization of blood vessels, organ blood flow, and tissue perfusion prior to, during, and after organ transplant, reconstructive, and minimally invasive surgeries.
Hepatic Function Testing: Quantitative evaluation of liver blood flow, functional parenchymal reserve, and biliary clearance rates.
Ophthalmic Angiography: Imaging of retinal and choroidal vasculature to diagnose complex ocular conditions.
Lymphatic Mapping: Fluorescence visualization of lymph nodes and lymphatic channels in surgical oncology procedures.
Industry market research estimates that the U.S. market for Indocyanine Green for Injection generates annual sales exceeding $12 million to $15 million, with limited generic competition due to technical complexities involved in sterile lyophilized manufacturing.
Significance of 180-Day CGT Exclusivity
The USFDA awards Competitive Generic Therapy (CGT) exclusivity under the FDA Reauthorization Act to incentivize pharmaceutical developers to bring generic alternatives for drugs with inadequate market competition. Because Zydus was designated as a first approved applicant for this generic formulation, the 180-day exclusivity period prevents the regulator from approving subsequent generic applications for the same product during the commercial window.
Capital goods and generic healthcare analysts note that 180-day CGT exclusivity yields significantly higher market share retention and favorable pricing power compared to standard generic launches. The approval adds momentum to Zydus Lifesciences' growing generic injectables pipeline, which spans complex formulations, oncology therapies, and specialized diagnostic products.
Official Sources
Regulatory filings detailing the final product clearance were submitted in compliance with statutory disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Official documentation was published across statutory stock exchange repositories and regulatory archives.
"According to officials familiar with the regulatory approval, the 180-day CGT exclusivity designation enables Zydus Lifesciences to commercialize a crucial diagnostic imaging agent, bolstering supply chain resilience for U.S. healthcare providers while expanding the company's complex injectable portfolio."
Why It Matters
For U.S. Hospitals and Surgeons: Expands generic access to an essential optical imaging agent used during complex vascular, oncological, and organ transplant procedures.
For Patients: Enhances diagnostic drug availability, reducing the risk of clinical delays or shortages in critical diagnostic procedures.
For Investors and Healthcare Analysts: Demonstrates Zydus's execution capability in high-margin specialized injectables and strengthens revenue visibility in North American markets.
Key Facts at a Glance
Final Approval Granted: Zydus Lifesciences receives USFDA approval for Indocyanine Green for Injection, 25 mg/vial.
Exclusivity Awarded: Granted 180 days of Competitive Generic Therapy (CGT) exclusivity as a first approved applicant.
Manufacturing Center: To be produced at the group’s formulation facility in Jarod, India.
Portfolio Scale: Zydus has secured over 390 ANDA approvals and filed more than 460 generic drug applications since FY 2003-04.
Frequently Asked Questions (FAQ)
What is Indocyanine Green for Injection used for?
Indocyanine Green for Injection is an intravenous diagnostic dye used for fluorescence imaging of blood vessels, tissue perfusion, liver function testing, lymphatic mapping, and ophthalmic angiography.
What does 180-day CGT exclusivity mean for Zydus Lifesciences?
Competitive Generic Therapy (CGT) exclusivity provides Zydus with 180 days of sole generic market exclusivity in the United States, preventing other generic applicants from launching competing versions during that timeframe.
Where is the drug manufactured?
The generic injectable product will be manufactured at Zydus Lifesciences' specialized manufacturing site in Jarod, Gujarat, India.
Where are official corporate announcements for Zydus Lifesciences filed?
Statutory announcements and corporate disclosures are published directly on the official portals of the BSE India and the National Stock Exchange of India.
Source: Official regulatory announcements published by Zydus Lifesciences Limited, the U.S. Food and Drug Administration, BSE India, National Stock Exchange of India, and regulatory notices from the Ministry of Finance.
